- Acquired by Boston Scientific for $600M, Mar 2025
- Raised $60M Series C led by Andera Partners, Dec 2022
- Raised $9.8M Series B led by Accelmed, Dec 2017
About
SoniVie is a medical device company developing innovative ultrasound-based denervation systems for treating hypertensive disorders, including resistant hypertension and pulmonary hypertension. The company's therapeutic intravascular ultrasound (TIVUS) system is a dedicated therapeutic catheter that offers a treatment for pulmonary hypertension (PAH) and renal artery denervation (RDN). The TIVUS catheter is inserted into the pulmonary artery in a catheterization procedure and selectively damages nerves associated with disease activity without touching the vessel walls or damaging the adjacent tissues. This treatment may significantly slow disease progression. SoniVie's technology has received FDA Breakthrough Device Designations for both pulmonary arterial hypertension and renal artery denervation.
Funding history · 3 rounds · $73.3M total
Headcount over time
Q&A
- What is SoniVie's primary business?
- SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH) using its therapeutic intravascular ultrasound (TIVUS) catheter.
- When was SoniVie acquired and by whom?
- SoniVie was acquired by Boston Scientific in March 2025.
- What was SoniVie's most recent funding round?
- In January 2023, SoniVie raised $60,000,000 in a funding round led by Andera Partners.
- Where is SoniVie's headquarters located?
- SoniVie's headquarters is located in Rosh Haayin, Israel.
- What breakthrough device designations has SoniVie received from the FDA?
- SoniVie's TIVUS system received a breakthrough device designation from the FDA in September 2019 for pulmonary arterial hypertension and in December 2020 for renal artery denervation for resistant hypertension.
- What is the status of SoniVie's TIVUS system approval?
- The TIVUS system is currently approved for sale in markets regulated by the CE mark.
- What is the total amount of funding SoniVie has raised to date?
- SoniVie has raised a total of $73,260,000.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sonivie.com/ |
|---|
Identifiers & details
| Legal name | SoniVie Ltd. |
|---|---|
| Former names | Cardiosonic |
| Founded | 2014-8 |
| Employees (exact) | 5 |
| Offices | Saint Paul |
| Status reason | Acquired by Boston Scientific on Mar, 2025 |
Acquisitions & public offerings
Acquired by Boston Scientific 2025-03 $600.0M
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | sonivie.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515125789 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2014-08-27 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הולצמן חיים 2 רחובות |